After the latest round of data on bb2121 from bluebird and Celgene left some of the more, um, demanding analysts disappointed in terms of durability, the ante has been raised substantially on the bet they’re making on their second-gen CAR-T — bb21217.
Designed to rely more on memory cells to amp up the efficacy — a perfectly reasonable theory that relies heavily on mouse data for its proof-of-concept rationale — bb21217 debuted its first data snapshot at ASH on Sunday.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.Free Subscription